slides · global inventory
Problem Agitate Solution
Arc collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 26,550
Current window 1,651-1,680
Pages 885
Rows per page 30
Arc
1,651-1,680 of 26,550
10
The slide uses a visual representation of an antibody molecule with callouts to specific engineering improvements, supported by a scatter plot showing clinical precedent for half-life extension.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Aha Moment2 hits
11
Uses a visual metaphor of antibody combination to explain the therapeutic strategy.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Aha Moment2 hits
12
The slide uses a Venn diagram to represent the intersection of genetic targets and a bar chart to demonstrate the efficacy of patient selection.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Aha Moment2 hits
13
The slide uses a Gantt-style pipeline visualization to show progress of seven distinct programs.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Aha Moment2 hits
14
The slide uses a Gantt-style layout to show progress across Discovery, IND-Enabling, and Clinical stages.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Aha Moment2 hits
15
Includes a KOL quote and two charts: a bar chart for global sales and a line chart for market share.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Aha Moment2 hits
07
The slide uses a map to show regional prevalence and a nested circle diagram to show the funnel from total infected to treated patients.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction2 hits
11
Data presented at EASL 2022, AASLD 2022, GHS 2023.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet2 hits
12
Data presented at EASL 2022. Shows dual-axis line charts for viral load/ALT and bar charts for T-cell frequency.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet2 hits
13
Arbutus Biopharma | Investor Presentation Deck | 26 slidesArbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet2 hits
14
The slide outlines a clinical trial protocol with specific patient counts (n=12, n=8) and timeline milestones (weeks 1, 24, 28, 40, 52).Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet2 hits
15
Data presented at EASL 2023. Includes both a summary table of mean changes and individual patient trajectory charts.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet2 hits
16
Shows two parallel study arms with randomization at week 24/26.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet2 hits
17
Data presented at AASLD 2023; includes both a summary table and a longitudinal line chart with error bars.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet2 hits
18
Data presented at AASLD 2023. Shows ELISpot results for T cell responses and HBsAg levels.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet2 hits
25
The slide includes a financial disclaimer regarding cash balance and burn.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution2 hits
26
Arbutus Biopharma | Investor Presentation Deck | 26 slidesArbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution2 hits
05
The slide uses a process flow diagram to contrast time-to-diagnosis and a bar chart to illustrate the exponential mortality risk of delayed treatment.Bluejay | Investor Presentation Deck | 20 slides · Bluejay Diagnostics
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction2 hits
05
Enochian Biosciences | Investor Presentation Deck | 28 slidesEnochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Logic Chain2 hits
10
The slide uses a visual comparison to frame the problem of current therapeutic limitations.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Problem (Identify pain)2 hits
07
Exscientia | Investor Presentation Deck | 69 slidesExscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction2 hits
08
The slide uses a hub-and-spoke style diagram to show how different technical capabilities feed into and are informed by precision medicine.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction2 hits
07
The slide uses a map-based hub-and-spoke visual to connect specific industry pain points to the global supply chain.Freightos | Investor Presentation Deck | 33 slides · Freightos
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction2 hits
03
Uses screenshots of competitor products with red circles highlighting disclaimers that they do not check for heart attacks.HeartBeam | Investor Presentation Deck | 18 slides · HeartBeam
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction2 hits
04
Uses a binary choice framework to highlight the negative outcomes of patient uncertainty.HeartBeam | Investor Presentation Deck | 18 slides · HeartBeam
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction2 hits
06
Includes a disclaimer at the bottom regarding FDA status.HeartBeam | Results Presentation Deck | 19 slides · HeartBeam
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction2 hits
04
Hyperfine | Investor Presentation Deck | 24 slidesHyperfine | Investor Presentation Deck | 24 slides · Hyperfine
Conference presentation Investor relations Beat · Problem (Identify pain)2 hits
19
The slide uses two scatter plots to compare diagnostic performance metrics against competitors like Guardant Health, CellMax Life, and Cologuard.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations Beat · Market Size2 hits
05
Uses a personal narrative (Shay) to humanize the disease progression alongside clinical data.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Problem2 hits
06
The slide uses a biological mechanism-of-action diagram to illustrate how the two components of PrimeC address specific cellular stressors in ALS.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Agitate2 hits